Arcturus Therapeutics is trading 6.6% up at $15.29 after renewed investor focus on ARCT-810, its mRNA therapy for OTC deficiency.
- Phase 2 enrollment and dosing are complete; additional data and a regulatory plan are expected during the third quarter of 2026.
- Shares have gained sharply across recent sessions amid enthusiasm for mRNA biotechnology and ahead of the Helsinki symposium presentation on patient dietary-intake and biochemical findings.
- The broader biotech sector is also higher, adding momentum.